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Abstract. Several preclinical studies have found a poor cor-
relation between the ex vivo platelet inhibitory potency
and the in vivo antithrombotic ef~cacy of GPIIb/IIIa recep-
tor antagonists. The present study was designed to examine
the differential in vitro potencies of c7E3, MK-383, DMP-
728, and SM-20302 in inhibiting ex vivo platelet aggregation
under normocalcemic and hypocalcemic conditions. Human
blood was collected in either trisodium citrate (0.37%) or
PPACK (20 lg/mL). Platelet aggregation assays were per-
formed in platelet-rich plasma from citrate-anticoagulated
blood (cPRP) and PPACK-anticoagulated blood (pPRP) us-
ing ADP (20 lM) and TRAP (10 lM) as agonists in the
presence of c7E3, MK-383, DMP-728, or SM-20302. The con-
centrations of ionized calcium in cPRP was 16–19 times
lower than that in pPRP. The IC50 of c7E3 for inhibiting
ADP-induced platelet aggregation  in  cPRP (2.76 6 0.11
lg/mL) was 1.6 times lower than that in pPRP (4.46 6 0.48
l/mL; P , 0.05). Similarly, the IC50 for c7E3 for inhibiting
TRAP-induced platelet aggregation in cPRP (4.52 6 0.34
lg/mL) was 1.7 times lower than that in pPRP (7.69 6 0.43
lg/mL; P , 0.05). MK-383, DMP-728, and SM-20302 also
demonstrated 1.96-, 1.15-, and 1.43-fold lower IC50 values,
respectively, in cPRP as compared with pPRP. Chelation of
ionized calcium in pPRP led to a progressive increase in
platelet inhibition by all the antagonists. These results sug-
gest  that  the  observed  in  vitro  inhibitory potency of a
GPIIb/IIIa receptor antagonist is markedly enhanced when
trisodium citrate is  used as an anticoagulant to collect
blood for ex vivo assay. These ~ndings indicate that dosing
regiments for GPIIb/IIIa receptor antagonists based on the
platelet inhibition pro~le in citrate may provide misleading
information with respect to their true in vivo antithrom-
botic ef~cacy.
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Preclinical and clinical evaluations of GPIIb/IIIa re-
ceptor antagonists rely heavily on the relationship be-
tween ex vivo platelet inhibition assays, and in vivo
antithrombotic ef~cacy. The ex vivo platelet aggrega-
tion assay utilizes trisodium citrate as the conventional
anticoagulant for the collection of whole blood to be
used for the preparation of platelet-rich plasma (PRP).
Unfortunately, the reduction or removal of the ionized
calcium concentration from the PRP by trisodium cit-
rate induces a morphological change in the platelets [1]
and in_uences the stability of the GPIIb/IIIa complex
[2–4] and the divalent cation-dependent binding of
RGD ligands to the GPIIb/IIIa receptor [5,6]. Under
such circumstances, the ex vivo platelet aggreagation
studies may falsely reveal a greater antiplatelet po-
tency  of a particular antagonist of the glycoprotein
receptor.
It is important to note that both intracellular and
extracellular calcium play an important role in platelet
aggregation. Intracellular calcium in_uences the plate-
let shape change, exposure of GPIIb/IIIa receptors,
and ~brinogen binding [7–9]. On the other hand, con-
trol of the extracellular ionized calcium concentration,
within the physiologic range (1 m/M), is essential for
maintaining the GPIIb/IIIa receptor complex in a con-
formation capable of interacting with soluble ~brino-
gen on exposure of the platelet to an agonist. Complex-
ing extracellular ionized calcium ions to the four
repetitive domains (resembling calmodulin or troponin
C) on the GPIIb subunit of the integrin receptor plays
a role in the stability of the receptor complex [10,11].
In addition to the four calcium-binding sites, there is a
proposed ~fth site, known as the metal ion-dependent
adhesion site (MIDAS) domain, on the GPIIIa [12–14].
Divalent cations, such as Ca21 and Mn21, can compete
with RGD-containing ligands or synthetic antagonists
to bind to the activated GPIIb/IIIa receptor [15,16].
Although trisodium citrate may not alter the intracel-
lular calcium ion concentration, it can certainly do so
extracellularly in the platelet suspension, and conse-
quentially alter receptor function. In addition, removal
of calcium from the receptor sites may enhance the
binding of GPIIb/IIIa antagonists and may, therefore,
introduce an artifact in evaluating the in vivo ef~cacy
of the antagonists.
We have provided evidence for this phenomenon
with TP-9201, a small, peptidomimetic, cyclic
GPIIb/IIIa receptor antagonist [17]. In this study two
dosing regimens (120 l/kg 1 3 l/kg/min and 185 l/kg 1
5 l/kg/min) were used, with the expectation of a dose-
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related effect on platelet inhibition and antithrombotic
ef~cacy. However, both the dosing regimens com-
pletely inhibited (.90%) ADP-induced platelet aggre-
gation in citrated PRP (cPRP). In heparinized PRP
(hPRP), the low and high doses of TP-9201 produced
21% and 45% inhibition of platelet aggregation, respec-
tively. Dose-dependent prolongation of bleeding time
and prevention of thrombosis were also observed. A
similar observation has been reported by Collen et al.
using TP-9201 [18]. In these studies the GPIIb/IIIa
receptor antagonist exhibited enhanced potency based
on the ex vivo assay in citrated blood. We aimed to
investigate whether chelation of calcium by trisodium
citrate was responsible for this phenomenon. Accord-
ingly, the objective of the present investigation was to
assess the differential in vitro potencies of structurally




c7E3 (ReoPro) was provided by Dr. Robert E. Jordan
(Centocor, Inc., Malvern, PA). DMP-728 was a gift from
Dr. Shaker A. Mousa (DuPont Merck Pharmaceutical
Co., Wilmington, DE). MK-383 was obtained from Dr.
Claus J. Schmitges (E. Merck, Darmstadt, Germany).
SM-20302 was provided by Sumitomo Pharmaceuticals
(Osaka, Japan). All drugs were dissolved in sterile sa-
line. Trisodium citrate, adenosine diphosphate (ADP),
PPACK (D-phenylalanyl-L-propyl-L-arginyl-chlo-
romethyl ketone), and standard reagents were pur-
chased from Sigma Chemical Co. (St. Louis, MO).
Heparin sodium injection, USP (1000 U/mL) was pur-
chased from Elkins-Sinn. (Cherry Hill, NJ). TRAP
(SFLLRN-NH, 10 lM) was synthesized in the Protein
and Carbohydrate Structure Core Laboratory of the
University of Michigan Multipurpose Arthritis Center.
Blood collection
After informed consent, blood was collected from
healthy, drug-free human volunteers in either triso-
dium citrate (1:10 citrate to blood; ~nal concentration,
0.37%), PPACK (~nal concentration, 20 lg/mL of
blood), or heparin (~nal concentration, 10 U/mL).
Platelet aggregation studies
The whole blood cell count was determined with an
H-10 cell counter (Texas International Laboratories,
Houston, TX). Platelet-rich plasma (PRP) was ob-
tained by centrifuging anticoagulated whole blood at
1000 rpm for 5 minutes (140 g). PPP was prepared after
the PRP was removed by centrifuging the remaining
blood at 2000 g for 10 minutes and discarding the bot-
tom cellular layer. All centrifugations were done at
218C. The PRP obtained from citrated blood (cPRP)
and PPACK-anticoagulated blood (pPRP) was diluted
with the respective PPP to achieve a platelet count of
200,000/lL. Ex vivo platelet aggregation was assessed
by established spectrophotometric methods with a
four-channel aggregometer (BioData-PAP-4, Bio Data
Corp., Hatboro, PA) by recording the increase in light
transmission through a stirred suspension of PRP (410
lL). Aggregation studies were performed after sam-
ples were rewarmed to 378C. Aggregation was induced
with ADP (20 lM) or TRAP (SFLLRN-NH2; 10 lM).
All antagonists were incubated in PRP for 1 minute,
after which the platelet agonists were added. Agonists
and antagonists (c7E3, DMP-728, MK-383, and  SM-
20302) were added in a volume of 50 lL, and the extent
of inhibition was examined by light transmittance ag-
gregometry. Values for platelet aggregation were ex-
pressed as the percentage of light transmission stand-
ardized to PRP and PPP samples yielding 0% and 100%
light transmission, respectively. The IC50 values were
determined from a sigmoidal dose-response relation-
ship using GraphPad Prism (Version 2.0a, GraphPad
Software, Inc.). A minimum of 8–10 concentrations
were used for all antagonists.
To study the effect of calcium chelation on the inhibi-
tory potency of GPIIb/IIIa receptor antagonists, vary-
ing concentrations of trisodium citrate were added to
pPRP and the aggregatory response of ADP (20 lM)
was examined in the presence of a subthreshold con-
centration of each antagonist.
Concentration of ionized calcium in
plasma
Whole blood samples were collected in individual tubes
containing either trisodium citrate, PPACK, or heparin
as the anticoagulant. The blood samples were proc-
essed for the preparation of PPP and PRP as described
previously and were analyzed for ionized calcium con-
centration using an ion analyzer (Nova-6, Nova
Biomedical Instruments, Waltham, MA).
Statistical analysis
The data are expressed as the mean 6 SEM. An un-
paired t-test was used to assess differences in values
obtained in cPRP and pPRP. Values were determined
to be statistically different at a level of P , 0.05.
Results
Concentration of ionized calcium in
plasma using different anticoagulants
The concentration of ionized calcium was measured in
PRP and PPP samples that were anticoagulated in-
itially with either trisodium citrate, PPACK, or hepa-
rin (Table 1). The mean ionized calcium concentrations
in the PRP prepared from citrate, PPACK, and hepa-
rin were 0.056, 1.08, and 0.98 mM, respectively. Simi-
larly, the mean ionized calcium concentrations in the
PPP samples prepared from citrate, PPACK, or hepa-
rin were 0.059, 1.13, and 0.971 mM, respectively. The
concentration of ionized calcium in citrated plasma was
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19 times lower than that in heparinized plasma (P ,
0.05) and 16–17 times lower than in PPACK anticoagu-
lated plasma (P , 0.05).
In vitro potency of GPIIb/IIIa receptor
antagonists
The platelet inhibition pro~le in cPRP differed
signi~cantly from that in pPRP (Table 2). For example,
the estimated IC50 for c7E3 for inhibiting ADP-induced
platelet aggregation in cPRP was 1.6 times lower than
that  in pPRP. Figure 1 is a representative platelet
inhibition pro~le of c7E3 (5 lg/mL) in cPRP and pPRP
treated with 20 lM ADP. It is evident that 5 lg/mL of
c7E3, which is the IC50 for ADP-induced platelet ag-
gregation in pPRP, produced complete inhibition of the
aggregation response in cPRP. The IC50 values for in-
hibiting TRAP-induced   platelet aggregation were
higher, but the difference in cPRP and pPRP was 1.7-
fold (P , 0.05). MK-383, DMP-728, and SM-20302 also
demonstrated 1.96-, 1.15-, and 1.43-fold lower IC50 val-
ues, respectively, in cPRP compared with that in pPRP.
Effect of calcium chelation on the
platelet inhibitory action of GPIIb/IIIa
receptor antagonists
To examine the inhibitory effects of the antagonists in
the presence of varying calcium concentrations, triso-
dium citrate was added to pPRP samples (Figure 2).
Irrespective of the structure, all the antagonists pro-
duced negligeable inhibition when the ionized calcium
was 0.9 mM to 1 mM. Further depletion of calcium led
to accentuation of the inhibitory response of the sub-
threshold concentrations of all the antagonists.
Discussion
The discordance between the IC50 values obtained us-
ing trisodium citrate and PPACK can be explained by
the varying concentration of ionized calcium in the two
assay media. We noted that the ionized calcium concen-
tration in cPRP was 16–19 times less than that in
hPRP and pPRP. A physiologic concentration of ex-
tracellular ionized calcium is critical to maintain the
integrity of the GPIIb/IIIa heterodimer complex on
the platelet surface [2,19] and ~brinogen binding to the
activated integrin receptor [20–22]. The concentration
of ionized calcium can also in_uence the formation of
GPIIb/IIIa heterodimers [23], and the GPIIb/IIIa and
~brinogen interaction [5]. Human platelets incubated
with the extracellular calcium chelators, EDTA and
EGTA, undergo morphological changes [1] and fail to
aggregate [2,3,24], or bind to ~brinogen in response to
ADP [9,20,22]. Winters et al. [25] demonstrated that
the binding of MoAb 10E5, a complex speci~c anti-
GPIIb/IIIa antibody, to the platelets was reduced by
80% under the conditions of complete absence of cal-
cium and a temperature of 378C. The extent to which
the platelet response is altered depends on the degree
of calcium chelation. Trisodium citrate is not as effec-
tive as EDTA in chelating extracellular calcium, but it
does induce hypocalcemic conditions as indicated by
our data. In the present study, the presence of a
GPIIb/IIIa receptor antagonist in cPRP may have
acted in concert with low Ca12 concentration to reduce
the platelet aggregation response, thereby yielding a
false indication of the drug’s in vivo potency in terms of
preventing platelet aggregation.
Investigation of the current literature on the pre-
clinical evaluation of GPIIb/IIIa receptor antagonists
indicates that trisodium citrate was the anticoagulant
used to collect blood for ex vivo platelet inhibition stud-
ies, and as a result there was discordance between the
ex vivo platelet inhibition data and the in vivo ef~cacy
Table 1. Effect of different anticoagulants on the
concentration of ionized calcium in human plasma samples
PPP PRP
Anticoagulant [Ca21] mM [Ca21] mM
Sodium citrate (0.37%, 0.056 6 0.003 0.059 6 0.003
n 5 7)
Heparin (10 U/mL, 1.08 6 0.05a 1.13 6 0.02a
n 5 5)
PPACK (20 lg/mL, 0.980 6 0.017a 0.971 6 0.015a
n 5 7)
aP , 0.05 as compared with trisodium citrate.
PRP 5 platelet-rich plasma.
Values are presented as the mean 6 SEM.
PPP 5 platelet-poor plasma;
Table 2. Effect of different anticoagulants on the potency (IC50) of GPIIb/IIIa antagonists in inhibiting human platelet aggregation
ADP (20 lM) TRAP (10 lM)
Drugs Citrate PPACK Citrate PPACK
c7E3 (n55, lg/mL) 2.76 6 0.11 4.46 6 0.48a 4.52 6 0.34 7.69 6 0.43a
MK-383 (n55, ng/mL) 25.00 6 1.76 49.04 6 1.10a 41.31 6 1.64 70.97 6 6.01a
DMP728 (n56, ng/mL) 29.55 6 1.89 34.21 6 2.31 38.64 6 1.41 55.21 6 3.33a
SM-20302 (n54, ng/mL) 11.59 6 0.87 16.64 6 0.94a 14.36 6 1.44 18.49 6 1.16
aP , 0.05 as compared with trisodum citrate.
Values are presented as the mean 6 SEM.
Ionized Ca21 and Ex Vivo Platelet Aggregation 25
data. For example, using c7E3 in a primate model of
carotid artery thrombosis, it was shown that the 0.15
mg/kg and 0.25 mg/kg doses had a similar ex vivo plate-
let inhibition pro~le (80–90%), but the incidence of oc-
clusion was 66% and 0% for the low and high doses,
respectively [26]. Lynch et al. [27] observed that a 3
lg/kg/min and 10 lg/kg/min infusion of MK-383 was
associated with a 90–100% and 100% inhibition of colla-
gen-induced platelet aggregation. However, in a canine
model of primary coronary artery thrombosis, only the
10 lg/kg/min regimen was effective. Similarly, the 0.1
and 1.0 mg/kg doses of DMP-728 produced 75–100%
and 90–100% inhibition of ADP-induced platelet aggre-
gation in cPRP, and the incidences of carotid artery
occlusion occlusion were 17% and 0% respectively. The
lack of correlation between platelet inhibition in cPRP
and the in vivo antithrombotic ef~cacy was also evi-
dent in previous  studies employing L-738, 167 [28],
SC-49992 [29], TP-9201 [17], and SM-20302 [30]. These
studies reinforce the concept that platelet aggregation
performed in cPRP is a poor indicator of the in vivo
activity of GPIIb/IIIa receptor antagonists.
Our in vitro data with GPIIb/IIIa receptor antago-
nists may help to provide a better understanding of the
outcome of the integrilin trials. Using four different
dosing strategies of integrilin (Epti~batide) in patients
scheduled for elective percutaneous interventions, it
was observed that administration of a bolus (90–180
lg/kg) followed by an infusion (0.5–1 lg/kg/min for 20
hours) did not result in a dose-related  inhibition of
ADP-induced platelet aggregation in cPRP. The maxi-
mum inhibition produced by all four dosing regimens
was 90% [31]. In the  IMPACT-II study [32] it was
noted that despite 70–78% inhibition of ADP-induced
platelet aggregation in cPRP, integrilin treatment did
not in_uence 6-month clinical outcomes after PTCA.
Recently Phillips et al. [33] provided evidence for the
integrilin discrepancy by demonstrating that the IC50
values for ADP and TRAP-induced platelet aggrega-
tion in cPRP were 4- and 7.5-fold lower than those in
pPRP. Furthermore, these investigators made use of
PAC1, an antibody having binding properties that
mimic the binding of ~brinogen to GPIIb/IIIa. PAC1,
like ~brinogen, has similar divalent cation require-
ments for binding, requires platelet activation before
binding can occur, and its binding can be affected by
inhibitors of GPIIb/IIIa. The concentration of inte-
grilin required to inhibit PAC1 binding in cPRP was
lower than that required in pPRP, indicating that en-
hanced inhibition by integrilin in cPRP was the result
of enhanced inhibition of ~brinogen binding. The phar-
macodynamic determinations of the platelet aggrega-
tion inhibitory activity of integrilin, therefore, is en-
hanced by collection of blood samples with citrate as
the anticoagulant  [33]. The integrilin trials indicate
that an effective dosing regimen for in vivo inhibition
of platelet reactivity may correlate with less than 80%
inhibition of ex vivo platelet aggregation responses to
ADP and/or TRAP. Later the PURSUIT trials re-
vealed that a modi~ed and clinically effective dosing
regimen, guided by ex vivo aggregation studies done
in PPACK-PRP, and which did not inhibit completely
the platelet aggregation response, could be used with
relative safety. In contrast to integrilin, the differences
Fig. 1. A representative trace illustrating the effect of c7E3 (5 lg/mL) on platelet aggregation induced by ADP (20 lM). Platelet ag-
gregation was performed using PRP isolated from blood anticoagulated with trisodium citrate (cPRP) and PPACK (pPRP). Saline
or c7E3 was added to a stirred suspension of PRP 1 minute prior to the addition of ADP, and the run time for the assay was 10 min-
utes.
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in the IC50 values between cPRP and pPRP in our
study were smaller (about two fold for MK-383). This
may be due to the extent of calcium chelation in the two
studies. We used 0.37% of trisodium citrate, whereas
Phillips et al. used 0.57%.
In conclusion, using several structurally unrelated
inhibitors of the platelet GPIIb/IIIa receptor, our ob-
servations, which are in agreement with those of Phil-
lips et al. [33], suggest that the decrease in ionized
calcium ion concentration renders the platelets more
susceptible to inhibition by GPIIb/IIIa antagonists
when challenged with platelet agonists. The use of
PPACK, heparin, or hirudin as an anticoagulant dur-
ing the collection of the blood sample maintains the
ionized calcium concentration similar to that in the in
vivo situation. The latter approach may provide a
more accurate ex vivo assessment of platelet reactiv-
ity in response to aggregating agents,  and may be
more suited to the mechanistic study of platelet func-
tion, where it becomes essential to correlate the ex
vivo observation with  an  anticipated  in  vivo effect,
that is, prevention of arterial thrombosis. The use of
a proper anticoagulant should result in a better cor-
relation between the ex vivo and in vivo ~ndings, and
assist in maintaining an optimal dosing regimen while
avoiding or reducing the incidence of untoward effects
related to hemostasis.
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Fig. 2. Effect of ionized calcium on the inhibitory effect of subthreshold concentrations of GPIIb/IIIa receptor antagonists. Platelet
aggregation was induced by ADP (20 lM) using pPRP. Varying calcium concentrations were achieved by adding different concentra-
tions of trisodium citrate to pPRP.
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